{"id":"W2981636558","doi":"10.1016/j.jtho.2019.10.013","title":"Randomized Phase II Study of Paclitaxel plus Alisertib versus Paclitaxel plus Placebo as Second-Line Therapy for SCLC: Primary and Correlative Biomarker Analyses","year":2019,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":147,"is_retracted":false,"has_abstract":false,"ca_institutions":"Hôpital Charles-Le Moyne; Université de Sherbrooke; University of Alberta","funders":"Takeda Oncology; EMD Serono; National Institutes of Health; PharmaMar; Daiichi-Sankyo; G1 Therapeutics; Clovis Oncology; University of Texas Southwestern Medical Center; Merck Sharp and Dohme; Genzyme; Takeda Pharmaceuticals U.S.A.; Foundation Medicine; United Therapeutics Corporation; F. Hoffmann-La Roche; Ipsen Biopharmaceuticals; Novartis; Celgene; Merck; Spectrum Pharmaceuticals; Purdue University; MedImmune; Sanofi; GlaxoSmithKline; Roche; AbbVie; Genentech; Aeglea BioTherapeutics; Amgen; Daiichi Sankyo Europe; National Cancer Institute; Intuitive Surgical; Moderna; Pfizer; AstraZeneca; Purdue Pharma; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Paclitaxel; Hazard ratio; Internal medicine; Oncology; Placebo; Clinical endpoint; Population; Gastroenterology; Confidence interval; Randomized controlled trial; Chemotherapy; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004156435,0.003343039,0.006559975,0.001117661,0.0009086308,0.002062698,0.001915327,0.002763598,0.009534379],"category_scores_gemma":[0.003005133,0.001576582,0.002991175,0.001075933,0.002740935,0.002377333,0.0008482683,0.005746706,0.001898843],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001984717,"about_ca_system_score_gemma":0.002781334,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00184313,"about_ca_topic_score_gemma":0.004176921,"domain_scores_codex":[0.9984042,0.0008750547,0.00007967398,0.0003099113,0.00009652346,0.0002347117],"domain_scores_gemma":[0.9971301,0.0007883303,0.0005906827,0.0003825841,0.0002099596,0.0008984745],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9863826,0.006887478,0.0003437908,0.0001067338,0.0005305601,0.00001209344,0.00002372066,0.0002088906,0.001206256,0.00004273295,0.0002545181,0.004000621],"study_design_scores_gemma":[0.9201312,0.0772691,0.001147297,0.000009395464,0.0004479307,0.0000144937,0.00001944743,0.0002433132,0.0002854028,0.0001082884,0.000310207,0.00001386753],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9842977,0.002625073,0.001084184,0.0009230747,0.000971836,0.005581855,0.002357636,0.0002031508,0.001955599],"genre_scores_gemma":[0.9763277,0.002150184,0.002815275,0.001854228,0.0009915284,0.007327972,0.002638076,0.00007971152,0.005815458],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.009534379,"threshold_uncertainty_score":0.0318957,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1253425639402656,"score_gpt":0.5412142173577857,"score_spread":0.4158716534175201,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}